Patient characteristics among 100 severe COVID-19 patients in Brescia, Italy 10 days after Tocilizumab (TCZ) infusion
-
"One hundred patients were treated with TCZ (Table 1). The median age was 62 [IQR 57–71] and most patients were male (M/F: 88/12). Comorbidities were present in more than half of patients with hypertension being the most common one (46%), followed by obesity (31%), diabetes (17%) and cardiovascular disease (16%)"
-
"On admission the most common symptoms were fever (85%), dyspnea (73%) and cough (55%) with a median time from illness onset and hospital admission of 6 [IQR 4–8] days."
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Outcomes among 100 severe COVID-19 patients in Brescia, Italy 24–72 h after Tocilizumab (TCZ) infusion
Outcomes among 100 severe COVID-19 patients in Brescia, Italy 10 days after Tocilizumab (TCZ) infusion
Patient characteristics among 100 severe COVID-19 patients in Brescia, Italy 10 days after Tocilizumab (TCZ) infusion
Laboratory findings among 100 severe COVID-19 patients in Brescia, Italy 10 days after Tocilizumab (TCZ) infusion
Methods for tracking outcomes among 100 severe COVID-19 patients in Brescia, Italy 24–72 h after Tocilizumab (TCZ) infusion
Discussion from "Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy"